



Biotech Daily

Wednesday October 14, 2020

Daily news on ASX-listed biotechnology companies

- * **ASX DOWN, BIOTECH UP: AMPLIA UP 21%; OPTHEA DOWN 7%**
- * **NEXT SCIENCE SHARE PLAN RAISES \$5m; TOTAL \$15m**
- * **PHARMAXIS RECEIVES \$5m R&D TAX INCENTIVE**
- * **TALI DETECT, TRAIN ON SALE IN INDIA**
- * **BTC WINS ISO 1345 QUALITY CERTIFICATION**
- * **RECCE REQUESTS 'RECCE-327 ETHICS APPROVAL' TRADING HALT**
- * **RESPIRI REQUESTS 'CAPITAL RAISING' TRADING HALT**
- * **MAYNE \$1.6m SHARES, \$3.1m LOAN TO CEO SCOTT RICHARDS AGM**
- * **NOXOPHARM 3.25m DIRECTORS OPTIONS AGM**
- * **ALLAN GRAY REDUCES TO 8.9% OF IMPEDIMED**
- * **QUEST TAKES 6.3% OF KAZIA**
- * **JOHN MCBAIN, PICTON, 52nd CELEBRATION TAKE 14% OF RHINOMED**
- * **MEDICAL DEVELOPMENTS: BRENT MACGREGOR CEO, GORDON NAYLOR NED**
- * **LITTLE GREEN WA FACILITY WINS TGA MARIJUANA GMP LICENCE**
- * **L1 BELOW 5% IN CRESO**
- * **AMBER SCHWARZ, JAMBER BELOW 5% IN CRESO**
- * **MGC: ARTEMIC 'NOT TOXIC IN RATS' FOR COVID-19**
- * **STEMCELL, BLUE AQUA J-V FOR SINGAPORE SEA GRAPES**

MARKET REPORT

The Australian stock market fell 0.27 percent on Wednesday October 14, 2020, with the ASX200 down 16.5 points to 6,179.2 points. Eighteen of the Biotech Daily Top 40 stocks were up, 15 fell, four traded unchanged and three were untraded. All three Big Caps rose.

Amplia was the best, up 3.5 cents or 20.6 percent to 20.5 cents, with 1.9 million shares traded. Antisense and Medical Developments climbed 12 percent or more; Optiscan rose 9.1 percent; Patrys was up 5.3 percent; Immutep, Paradigm, Polynovo and Pro Medicus improved more than four percent; Starpharma was up 3.7 percent; Nanosonics and Pharmaxis rose more than two percent; Clinuvel, CSL, Cynata, Genetic Signatures and Imugene were up more than one percent; with Cochlear, Kazia, Resmed and Volpara up by less than one percent.

Opthea led the falls, down 22 cents or seven percent to \$2.93, with 1.3 million shares traded. LBT, Oncosil, Osprey, Prescient and Resonance lost more than three percent; Avita, Dimerix, Impedimed, Next Science, Orthocell and Telix were down more than one percent; with Cyclopharm, Mesoblast and Proteomics down by less than one percent.

NEXT SCIENCE

Next Science says it has raised \$5 million in an oversubscribed share purchase plan at \$1.18 a share to raise a total of \$15 million.

Last month, Next Science said it hoped to raise \$15 million in a \$10 million placement at \$1.20 a share and a \$5 million share purchase plan (BD: Sep 16, 2020).

Today, the company said it had received \$10 million through the placement, including \$2 million from major shareholder Walker Group Holdings.

Next Science said it received applications for \$9.2 million through the share plan, which was scaled back to \$5 million.

The company said the share plan issue price was at a two percent discount to the five-day volume weighted average price.

Next Science fell 1.5 cents or 1.2 percent to \$1.225.

PHARMAXIS

Pharmaxis says it has received \$5,048,452 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Pharmaxis said the rebate related to expenditure for the year to June 30, 2020.

Pharmaxis was up 0.2 cents or 2.2 percent to 9.2 cents with 1.5 million shares traded.

TALI DIGITAL

Tali says Tali Detect and Tali Train cognitive performance tools for childhood attention disorders are available for sale via on-line shops in India.

Tali said both tools would be available through both Apple and Android application stores and a full market launched was expected in 2021.

Tali managing director Glenn Smith said the release of Tali Detect and Tali Train in India was "a key milestone in our international expansion strategy and follows our achievement of Google for Education Partner status on a global basis".

"We are excited by the opportunities the release in the large Indian market provides, as we pursue our goal of becoming a global leader in the assessment and treatment of early childhood attention disorders," Mr Smith said.

Tali fell 0.1 cents or 3.45 percent to 2.8 cents with 18.6 million shares traded.

BTC HEALTH

BTC says its subsidiary BTC Speciality Health has achieved ISO 13485 certification for its quality management system.

BTC said it had met all required standards for a medical device company, following a detailed program of work, which included an independent audit.

Last year, the company said it paid \$6.3 million for the Admedus (now Anteris) hospital infusion business through BTC Specialty Health (BD: May 31, 2019).

BTC was untraded at 9.3 cents.

RECCE PHARMACEUTICALS

Recce has requested a trading halt pending an announced related to "ethics committee approval of Recce-327 topical antibiotic therapy for infected burn wounds".

Trading will resume on October 16, 2020 or on an earlier announcement.

Recce last traded down 4.5 cents or 4.1 percent at \$1.06.

RESPIRI

Respiri has requested a trading halt pending an announcement “in respect of the outcome of the capital raising initiative”.

Trading will resume on October 20, 2020 or on an earlier announcement.

Respiri last traded at 23.5 cents.

MAYNE PHARMA

Mayne says its annual general meeting will vote to issue chief executive officer Scott Richards \$1,600,000 in shares and a \$3,072,000 loan to acquire more shares.

Mayne said the shares would form part of a long-term incentive and the limited-recourse interest-free loan would be for five years.

The company said the number of shares under the loan would be calculated from the loan amount and would be divided by the five-day volume weighted average price to the grant date.

Mayne said the shares would vest subject to total shareholder return conditions, including 20 percent for a total shareholder return growth rate of eight percent and all shares for an annual total shareholder return growth rate of 15 percent.

The company said that if conditions were met, the shares would vest progressively at continuously increasing hurdles over five years, including 20 percent after the first test date of September 1 annually, 30 percent after the second test date and the remainder after the third test date.

Mayne said the meeting would vote to re-elect Roger Corbett and Nancy Dolan as directors and adopt its remuneration report.

The virtual meeting will be held at <https://web.lumiagm.com/314771877> on November 24, 2020 at 10am (AEDT).

Mayne was unchanged at 32 cents with 4.8 million shares traded.

NOXOPHARM

Noxopharm says its annual general meeting will vote to issue 3,000,000 incentive options to chair Frederik Bart and 250,000 options to Boris Patkin.

Noxopharm said the options would be exercisable at 31.5 cents within two years in three equal tranches, with tranche two and tranche three subject to five-day volume weighted average price milestones of 50 and 60 cents.

The company said it would also vote to adopt its remuneration report, elect Dr Graham Kelly, Mr Bart and Mr Patkin as directors, approve a 10 percent placement capacity and amend its Nora Goodridge Investments loan agreement, and issue shares to Mr Bart, Link and Goodridge Investments.

The meeting will be held virtually on November 17, 2020 at 2pm (AEDT) via: https://us02web.zoom.us/webinar/register/WN_KO-jA9ZhT9aziNwOckXCFA.

Noxopharm was unchanged at 41.5 cents.

IMPEDIMED

Allan Gray Australia says it has reduced its substantial shareholding in Impedimed from 104,869,050 shares (10.13%) to 95,805,454 shares (8.92%).

The Sydney-based Allan Gray said that between August 6 and October 5, 2020 it sold 9,063,596 shares for \$730,368 or 8.1 cents a share.

Impedimed fell 0.1 cents or 1.2 percent to 8.2 cents.

KAZIA THERAPEUTICS

Quest Asset Partners says it has become a substantial shareholder in Kazia with 7,215,790 shares or 6.27 percent of the company.

The Milsons Point, New South Wales-based Quest said that between June 9 and October 9, 2020 it acquired 5,010,704 shares for \$4,005,806 or 79.9 cents a share and disposed of 12,920 shares for \$6,859 or 53.1 cents a share.

Kazia was up half a cent or 0.6 percent to 80 cents.

RHINOMED

Dr John McBain, Picton Cove and Fifty-Second Celebration say they have increased their holding in Rhinomed from 31,999,025 shares (12.61%) to 35,752,640 shares (14.09%).

The Melbourne-based Dr McBain said that between October 5 and 14, 2020, Fifty-Second Celebration acquired 3,753,615 shares on-market for \$667,912 or 17.8 cents a share.

Rhinomed was unchanged at 18 cents.

MEDICAL DEVELOPMENTS INTERNATIONAL

Medical Developments says it has appointed former CSL Seqirus staff Brent MacGregor as chief executive officer and Gordon Naylor as a non-executive director.

Medical Developments said Mr MacGregor would be appointed effective from November 1, 2020 and Mr Naylor was appointed effective immediately.

The company said Mr MacGregor was previously the CSL Seqirus head of commercial operations, Novartis Vaccines US chief executive officer and was the former Sanofi Pasteur managing-director for Japan and Australia, head of the influenza and pneumococcal franchise and the executive director of strategic planning.

Medical Developments said Mr MacGregor held a Bachelor of Arts from the Ottawa, Ontario-based Carleton University, a Master of Arts from England's University of Reading and a Master of Business Administration from the Evanston, Illinois-based Northwestern University.

The company said that Mr Naylor previously held a range of roles with CSL for more than 30 years, including as chief financial officer and as head of CSL Seqirus.

Medical Developments said Mr Naylor held a Bachelor of Engineering, a Graduate Diploma in Computer Science and a Master of Business Administration, all from the University of Melbourne.

Medical Developments was up 64 cents or 12.2 percent to \$5.88 with 337,401 shares traded.

LITTLE GREEN PHARMA

Little Green Pharma says the Therapeutic Goods Administration has granted its Western Australia manufacturing facility a good manufacturing practice (GMP) licence.

Little Green said it planned to develop its capability to manufacture additional GMP-licenced marijuana products and other pharmaceutical formulations and would offer toll extraction and manufacturing services to other producers.

Little Green was up four cents or 13.8 percent to 33 cents with 1.3 million shares traded.

CRESO PHARMA

L1 Capital Global Opportunities Master Fund says it has ceased to be a substantial shareholder in Creso.

In July, the Cayman Islands-based L1 said it had ceased to be substantial in Creso, last week, said it had become substantial again with 11.99 percent, and yesterday said it had reduced its holding to 43,062,496 shares or 10.45 percent (BD: Jul 15, Oct 7, 13, 2020).

Today, L1 said that it disposed of 24,016,379 shares on October 12, 2020.

Biotech Daily calculates that L1 holds 2.8 percent of Creso.

Creso fell 0.1 cents or 3.2 percent to three cents with 53.8 million shares traded.

CRESO PHARMA

Jamber Investments says it has ceased to be a substantial shareholder in Creso.

In June, Jamber said it had increased and was diluted in Creso to 23,735,938 shares or 8.50 percent (BD: Jun 11, 2020).

Today, Jamber director James Schwarz for the Amber Schwarz Family account, said that it disposed of 3,172,320 shares on October 7, 2020.

Biotech Daily calculates that Jamber holds 3.0 percent of Creso.

MGC PHARMACEUTICALS

MGC says Artemic for Covid-19 is not toxic and has no pathological impact on major organs in a 24-rat pre-clinical in-vivo safety and toxicity study.

MGC said the results provided critical toxicological information for Artemic to support its current phase IIa trial on Covid-19 patients.

MGC was up 0.1 cents or 4.35 percent to 2.4 cents with 11.3 million shares traded.

STEMCELL UNITED

Stemcell says it has a joint venture, SCU Green Aqua Farm, with Blue Aqua International to cultivate and farm Caulerpa Lentillifera or sea grapes in Singapore.

In May, Stemcell said it had a two-year collaboration with Singapore's Temasek Polytechnic to research the commercial farming of seagrapes (BD: May 28, 2020).

Today, the company said the joint venture aimed "to implement part of a scalable circular economy in aquaculture, with plans to promote the ocean vegetable's unique qualities as a sustainable superfood and plant-based protein".

Stemcell said Blue Aqua specialised in aquaculture environment management, animal nutrition optimization and shrimp and fish farming in Singapore and Indonesia.

In its prospectus of June 29, 2015, Stemcell (then On Q Group) said it would extract Resina from *Daemonorops draco blume* or Dragon's Blood for traditional Chinese medicines, saying that "whether or not [traditional Chinese medicine] is believed, studies have shown that Chinese herbal medicine can be successful in treating a range of disorders" (BD: May 18, 2017).

In May, the company appointed Alan Dronkers as a "marijuana advisor" having lost "the king of cannabis" Nevil Schoemakers in 2017 (BD: Sep 29, 2017; May 7, 2020).

Stemcell was up 0.9 cents or 75 percent to 2.1 cents with 156.8 million shares traded.